The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

NCT05005741 · Unknown status

Last updated 2026-05-28

This clinical trial compares the effects of two medications, beinaglutide and dulaglutide, on blood sugar control and weight loss in adults with type 2 diabetes who are also overweight or obese.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 120 people Planned (estimated).

Who can join Ages 18–70 · all sexes

Timeline Started 2021-05 · est. completion 2023-12

Where 4 sites · China

What this study is testing ClinicalTrials.gov NCT05005741 ↗

Description as written by the study sponsor.

This study is a multi-center, open label, randomized controlled trial that main purpose of this study is to evaluate the differences of glucose control and weight loss between Beinaglutide and Dulaglutide in type 2 diabetes with overweight or or Obesity.

Treatments tested

Beinaglutide also known as GLP-1 receptor agonist Drug

Patients received beinaglutide subcutaneously three times a day for 16 weeks, the dose of beinaglutide escalate from 0.06mg to 0.2mg per 3-7 days according to subject's specific situation.
Dulaglutide also known as Trulicity, GLP-1 receptor agonist Drug

Patients received 1.5mg Dulaglutide subcutaneously once-weekly for 16 weeks.

Main thing measured	haemoglobin A1c(HbA1c)
Sponsor	Second Xiangya Hospital of Central South University
Conditions studied	Diabetes Mellitus, Type 2, Overweight or Obesity
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05005741 ↗